NEW YORK, July 1 (GenomeWeb News) - Berlin-based Europroteome and Altana Pharma have entered a collaboration to evaluate approaches to molecular profiling of tissue specimens from cancer patients.
Europroteome will apply its proprietary collection of purified cancer cells to analyze molecular expression of panel of cancer targets, which will then be compared with clinical data to assess disease-associated expression signatures. This data will be applied to define molecular targets for the development of therapeutics and diagnostics.
Financial terms were not disclosed.